Sumitomo Mitsui Trust Holdings Inc. decreased its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 1.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,644,922 shares of the company’s stock after selling 35,640 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc. owned about 0.26% of Teva Pharmaceutical Industries Limited worth $46,551,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in TEVA. San Francisco Sentry Investment Group CA purchased a new stake in Teva Pharmaceutical Industries Limited during the second quarter valued at $106,000. Kistler Tiffany Companies LLC raised its stake in Teva Pharmaceutical Industries Limited by 74.7% during the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after purchasing an additional 1,571 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its stake in Teva Pharmaceutical Industries Limited by 2.6% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,711 shares of the company’s stock valued at $123,000 after purchasing an additional 94 shares in the last quarter. Penserra Capital Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited in the third quarter valued at $129,000. Finally, Cutler Capital Management LLC purchased a new stake in shares of Teva Pharmaceutical Industries Limited in the second quarter valued at $133,000. 52.29% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Sumitomo Mitsui Trust Holdings Inc. Reduces Position in Teva Pharmaceutical Industries Limited (TEVA)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of U.S. & international copyright legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/11/20/sumitomo-mitsui-trust-holdings-inc-reduces-position-in-teva-pharmaceutical-industries-limited-teva.html.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at $13.55 on Monday. Teva Pharmaceutical Industries Limited has a 1 year low of $10.85 and a 1 year high of $39.08. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.66 and a current ratio of 0.96. The stock has a market cap of $12,740.00, a P/E ratio of 3.20 and a beta of 0.52.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be issued a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a dividend yield of 2.51%. The ex-dividend date of this dividend is Monday, November 27th. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is -16.01%.

Several equities research analysts have recently weighed in on the stock. BidaskClub downgraded shares of Teva Pharmaceutical Industries Limited from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 16th. Citigroup Inc. downgraded shares of Teva Pharmaceutical Industries Limited from a “buy” rating to a “neutral” rating and reduced their target price for the company from $32.00 to $19.00 in a research note on Wednesday, August 16th. Credit Suisse Group reissued an “outperform” rating and issued a $39.00 target price on shares of Teva Pharmaceutical Industries Limited in a research note on Wednesday, August 9th. Cantor Fitzgerald set a $17.00 target price on shares of Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research note on Monday, September 11th. Finally, Oppenheimer Holdings, Inc. downgraded shares of Teva Pharmaceutical Industries Limited from an “outperform” rating to a “market perform” rating and set a $41.00 target price on the stock. in a research note on Thursday, August 3rd. Seven equities research analysts have rated the stock with a sell rating, seventeen have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and an average price target of $21.88.

Teva Pharmaceutical Industries Limited Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Institutional Ownership by Quarter for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.